650 related articles for article (PubMed ID: 16597510)
21. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
Barrett AD; Teuwen DE
Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
[TBL] [Abstract][Full Text] [Related]
22. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
[TBL] [Abstract][Full Text] [Related]
23. An inactivated cell-culture vaccine against yellow fever.
Monath TP; Fowler E; Johnson CT; Balser J; Morin MJ; Sisti M; Trent DW
N Engl J Med; 2011 Apr; 364(14):1326-33. PubMed ID: 21470010
[TBL] [Abstract][Full Text] [Related]
24. Adverse event reports following yellow fever vaccination.
Lindsey NP; Schroeder BA; Miller ER; Braun MM; Hinckley AF; Marano N; Slade BA; Barnett ED; Brunette GW; Horan K; Staples JE; Kozarsky PE; Hayes EB
Vaccine; 2008 Nov; 26(48):6077-82. PubMed ID: 18809449
[TBL] [Abstract][Full Text] [Related]
25. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.
Belsher JL; Gay P; Brinton M; DellaValla J; Ridenour R; Lanciotti R; Perelygin A; Zaki S; Paddock C; Querec T; Zhu T; Pulendran B; Eidex RB; Hayes E
Vaccine; 2007 Dec; 25(50):8480-5. PubMed ID: 18023511
[TBL] [Abstract][Full Text] [Related]
26. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.
Kengsakul K; Sathirapongsasuti K; Punyagupta S
J Med Assoc Thai; 2002 Jan; 85(1):131-4. PubMed ID: 12075714
[TBL] [Abstract][Full Text] [Related]
27. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
Rafferty E; Duclos P; Yactayo S; Schuster M
Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
[TBL] [Abstract][Full Text] [Related]
28. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD).
Seligman SJ
Vaccine; 2014 Oct; 32(44):5769-75. PubMed ID: 25192973
[TBL] [Abstract][Full Text] [Related]
29. [YEL-AND meningoencephalitis in a 4-year-old boy consecutive to a yellow-fever vaccine].
Gerin M; Wroblewski I; Bost-Bru C; N'guyen MA; Debillon T
Arch Pediatr; 2014 Apr; 21(4):384-7. PubMed ID: 24630625
[TBL] [Abstract][Full Text] [Related]
30. Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for Arboviruses with clinical and immunological insights.
Le Hir A; Durand GA; Boucraut J; Garnier A; Mura M; Diamantis S; Carles M; Durand C; Schweitzer C; Audouard C; Decroix V; Boyez R; Van Dendriessche A; Leclancher A; Kaphan E; Barbat du Closel L; Verdon R; du Cheyron D; Vabret A; Vergnon D; Grard G; Charrel R; de Lamballerie X; Eldin C
J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38123499
[TBL] [Abstract][Full Text] [Related]
31. Adverse event reports following yellow fever vaccination, 2007-13.
Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
[TBL] [Abstract][Full Text] [Related]
32. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.
McMahon AW; Eidex RB; Marfin AA; Russell M; Sejvar JJ; Markoff L; Hayes EB; Chen RT; Ball R; Braun MM; Cetron M;
Vaccine; 2007 Feb; 25(10):1727-34. PubMed ID: 17240001
[TBL] [Abstract][Full Text] [Related]
33. Yellow fever vaccination: how much is enough?
Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
Vaccine; 2005 Jun; 23(30):3908-14. PubMed ID: 15917112
[TBL] [Abstract][Full Text] [Related]
34. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
[TBL] [Abstract][Full Text] [Related]
35. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
[TBL] [Abstract][Full Text] [Related]
36. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
Collaborative Group for Studies with Yellow Fever Vaccine
Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
[TBL] [Abstract][Full Text] [Related]
37. Yellow fever vaccine: worthy friend or stealthy foe?
Seligman SJ; Casanova JL
Expert Rev Vaccines; 2016 Jun; 15(6):681-91. PubMed ID: 27087465
[TBL] [Abstract][Full Text] [Related]
38. Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases.
Receveur MC; Thiébaut R; Vedy S; Malvy D; Mercié P; Bras ML
Clin Infect Dis; 2000 Sep; 31(3):E7-8. PubMed ID: 11017859
[TBL] [Abstract][Full Text] [Related]
39. Yellow fever vaccines and international travelers.
Barnett ED; Wilder-Smith A; Wilson ME
Expert Rev Vaccines; 2008 Jul; 7(5):579-87. PubMed ID: 18564013
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy and safety of vaccination against yellow fever of persons traveling to endemic areas].
Dabrowska MM; Flisiak R
Przegl Epidemiol; 2010; 64(2):319-22. PubMed ID: 20731245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
